CHMP expresses doubts on Puma's neratinib

Puma Biotechnology Inc. (NASDAQ:PBYI) said EMA's CHMP communicated a "negative trend vote" for its MAA for neratinib as extended adjuvant treatment of

Read the full 226 word article

User Sign In